Identification of Imidazo[1,2-]pyridazine TYK2 Pseudokinase Ligands As Potent and Selective Allosteric Inhibitors of TYK2 Signalling

Overview

Journal Medchemcomm

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2018 Aug 16

PMID 30108788

Citations 14

Authors

R Moslin

D Gardner

J Santella

Y Zhang

J V Duncia

C Liu

J Lin

J S Tokarski

J Strnad

D Pedicord

J Chen

Y Blat

A Zupa-Fernandez

L Cheng

H Sun

C Chaudhry

C Huang

C DArienzo

J S Sack

J K Muckelbauer

C Chang

J Tredup

D Xie

N Aranibar

J R Burke

P H Carter

D S Weinstein

Affiliations

Soon will be listed here.

Abstract

As a member of the Janus (JAK) family of non-receptor tyrosine kinases, TYK2 mediates the signaling of pro-inflammatory cytokines including IL-12, IL-23 and type 1 interferon (IFN), and therefore represents an attractive potential target for treating the various immuno-inflammatory diseases in which these cytokines have been shown to play a role. Following up on our previous report that ligands to the pseudokinase domain (JH2) of TYK2 suppress cytokine-mediated receptor activation of the catalytic (JH1) domain, the imidazo[1,2-]pyridazine (IZP) was identified as a promising hit compound. Through iterative modification of each of the substituents of the IZP scaffold, the cellular potency was improved while maintaining selectivity over the JH1 domain. These studies led to the discovery of the JH2-selective TYK2 inhibitor , which provided encouraging systemic exposures after oral dosing in mice. Phosphodiesterase 4 (PDE4) was identified as an off-target and potential liability of the IZP ligands, and selectivity for TYK2 JH2 over this enzyme was obtained by elaborating along selectivity vectors determined from analyses of X-ray co-crystal structures of representative ligands of the IZP class bound to both proteins.

Citing Articles

Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways.

Johnson B, Cheng L, Koenitzer J, Catlett I, Schafer P Front Immunol. 2024; 15:1437512.

PMID: 39403378 PMC: 11472182. DOI: 10.3389/fimmu.2024.1437512.

Synthesis, characterization, and molecular modeling of phenylenediamine-phenylhydrazine-formaldehyde terpolymer (PPHF) as potent anti-inflammatory agent.

Mujafarkani N, Bassey V, Tokono J, Ahamed A, Benjamin I, Agurokpon D Heliyon. 2023; 9(7):e18067.

PMID: 37483726 PMC: 10362139. DOI: 10.1016/j.heliyon.2023.e18067.

The pyridazine heterocycle in molecular recognition and drug discovery.

Meanwell N Med Chem Res. 2023; :1-69.

PMID: 37362319 PMC: 10015555. DOI: 10.1007/s00044-023-03035-9.

Novel TYK2 Inhibitors with an -(Methyl- )pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases.

Liu F, Wang B, Liu Y, Shi W, Tang X, Wang X ACS Med Chem Lett. 2022; 13(11):1730-1738.

PMID: 36385928 PMC: 9661719. DOI: 10.1021/acsmedchemlett.2c00334.

New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib.

Marcuzzi A, Rimondi E, Melloni E, Gonelli A, Grasso A, Barbi E Pharmaceuticals (Basel). 2022; 15(3).

PMID: 35337171 PMC: 8955311. DOI: 10.3390/ph15030374.

References

Luo H, Rose P, Barber D, Hanratty W, Lee S, Roberts T . Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol Cell Biol. 1997; 17(3):1562-71. PMC: 231882. DOI: 10.1128/MCB.17.3.1562. View

Liang J, Van Abbema A, Balazs M, Barrett K, Berezhkovsky L, Blair W . Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. J Med Chem. 2013; 56(11):4521-36. DOI: 10.1021/jm400266t. View

Rodig S, Meraz M, White J, Lampe P, Riley J, Arthur C . Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 1998; 93(3):373-83. DOI: 10.1016/s0092-8674(00)81166-6. View

Lupardus P, Ultsch M, Wallweber H, Kohli P, Johnson A, Eigenbrot C . Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc Natl Acad Sci U S A. 2014; 111(22):8025-30. PMC: 4050602. DOI: 10.1073/pnas.1401180111. View

Boudeau J, Miranda-Saavedra D, Barton G, Alessi D . Emerging roles of pseudokinases. Trends Cell Biol. 2006; 16(9):443-52. DOI: 10.1016/j.tcb.2006.07.003. View

Couturier N, Bucciarelli F, Nurtdinov R, Debouverie M, Lebrun-Frenay C, Defer G . Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain. 2011; 134(Pt 3):693-703. DOI: 10.1093/brain/awr010. View

Saharinen P, Silvennoinen O . The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem. 2002; 277(49):47954-63. DOI: 10.1074/jbc.M205156200. View

Tokarski J, Zupa-Fernandez A, Tredup J, Pike K, Chang C, Xie D . Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain. J Biol Chem. 2015; 290(17):11061-74. PMC: 4409266. DOI: 10.1074/jbc.M114.619502. View

Min X, Ungureanu D, Maxwell S, Hammaren H, Thibault S, Hillert E . Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2). J Biol Chem. 2015; 290(45):27261-27270. PMC: 4646372. DOI: 10.1074/jbc.M115.672048. View

10.

Chen M, Cheng A, Candotti F, Zhou Y, Hymel A, Fasth A . Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol. 2000; 20(3):947-56. PMC: 85212. DOI: 10.1128/MCB.20.3.947-956.2000. View

11.

Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S . Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity. 2006; 25(5):745-55. DOI: 10.1016/j.immuni.2006.09.009. View

12.

Dendrou C, Cortes A, Shipman L, Evans H, Attfield K, Jostins L . Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med. 2016; 8(363):363ra149. PMC: 5737835. DOI: 10.1126/scitranslmed.aag1974. View

13.

Menet C, Mammoliti O, Lopez-Ramos M . Progress toward JAK1-selective inhibitors. Future Med Chem. 2015; 7(2):203-35. DOI: 10.4155/fmc.14.149. View

14.

Furie R, Khamashta M, Merrill J, Werth V, Kalunian K, Brohawn P . Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017; 69(2):376-386. PMC: 5299497. DOI: 10.1002/art.39962. View

15.

Oyamada A, Ikebe H, Itsumi M, Saiwai H, Okada S, Shimoda K . Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis. J Immunol. 2009; 183(11):7539-46. DOI: 10.4049/jimmunol.0902740. View

16.

Kreins A, Ciancanelli M, Okada S, Kong X, Ramirez-Alejo N, Kilic S . Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med. 2015; 212(10):1641-62. PMC: 4577846. DOI: 10.1084/jem.20140280. View

17.

Vincenti F, Tedesco Silva H, Busque S, OConnell P, Friedewald J, Cibrik D . Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant. 2012; 12(9):2446-56. DOI: 10.1111/j.1600-6143.2012.04127.x. View

18.

Clark J, Flanagan M, Telliez J . Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014; 57(12):5023-38. DOI: 10.1021/jm401490p. View

19.

Ban M, Goris A, Lorentzen A, Baker A, Mihalova T, Ingram G . Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum Genet. 2009; 17(10):1309-13. PMC: 2782567. DOI: 10.1038/ejhg.2009.41. View

20.

Kieltyka K, Zhang J, Li S, Vath M, Baglieri C, Ferraro C . A high-throughput bioanalytical platform using automated infusion for tandem mass spectrometric method optimization and its application in a metabolic stability screen. Rapid Commun Mass Spectrom. 2009; 23(11):1579-91. DOI: 10.1002/rcm.4037. View